What Causes Long COVID Symptoms to Persist in Some Patients But Not Others?
Introduction
Long COVID, defined as persistent symptoms lasting at least two to three months after acute SARS-CoV-2 infection, affects an estimated 10-36% of infected individuals globally, yet the reasons why some patients recover while others develop chronic symptoms remain multifactorial and incompletely understood [1]. Research demonstrates that the persistence of long COVID symptoms involves a complex interplay of demographic factors, clinical characteristics, biological mechanisms, and host factors that collectively determine whether an individual progresses toward recovery or sustained illness.
Demographic and Clinical Risk Factors for Symptom Persistence
Multiple epidemiological studies have identified consistent demographic patterns associated with symptom persistence. Female sex represents one of the strongest and most consistently identified risk factors across diverse populations [2], [1], [3]. Female patients demonstrate significantly higher rates of complaints including fatigue, insomnia, memory disturbance, and paresthesia compared to their male counterparts, particularly among those with persistent symptoms beyond six months [4]. Beyond sex differences, advanced age consistently emerges as a predictor of long COVID persistence, with individuals over 60 years demonstrating increased susceptibility [5]. Furthermore, individuals with pre-existing comorbidities—including obesity, diabetes, hypertension, asthma, and other chronic conditions—face substantially elevated odds of developing persistent symptoms [2], [1], [6].
The severity of the acute COVID-19 infection itself profoundly influences the trajectory toward persistence. Notably, more initial symptoms during the acute phase correlate paradoxically with both increased and decreased risk depending on the timeframe examined. While individuals experiencing severe acute illness or requiring intensive care unit admission show elevated risk for long-term symptom persistence, those reporting more symptoms in the first six months post-infection show approximately 30% reduced odds of long-term symptoms at one year [7]. This suggests that the initial symptom burden may indicate individuals capable of mounting robust immune responses that eventually resolve. However, ICU admission and dysgeusia independently predicted long COVID persistence in some cohorts [8], indicating that the nature and type of acute-phase complications matter significantly.
The Role of Immune Dysregulation and Inflammation
Persistent immune dysregulation fundamentally distinguishes individuals who develop long-lasting symptoms from those who recover. Research reveals that long COVID patients maintain elevated inflammatory markers months after infection, including elevated interleukin-6 and tumor necrosis factor levels that correlate directly with ongoing symptoms such as lung fibrosis and cognitive impairment [9]. This chronic inflammatory state appears to stem from multiple biological phenomena operating simultaneously. A key mechanism involves impaired humoral immunity and persistent antigen exposure; researchers have observed that individuals with long COVID demonstrate increased SARS-CoV-2-specific CD4+ and CD8+ T-cell responses and elevated antibody affinity, suggesting chronic immune activation driven by persistent pathogenic antigen [10].
Beyond persistent SARS-CoV-2 antigen, immune dysregulation manifests through alterations in specific immune cell populations. Significantly, a reduction in CD8+ T-cell counts associates with severe fatigue and cognitive dysfunction, whereas memory CD8+ T cells maintain central positions in inflammatory signaling networks in long COVID patients [11]. The persistence of this immune dysregulation appears supported by an unusual mechanism: elevated plasma IgG against the nucleocapsid in long COVID patients may indicate either frequent reinfections, greater infection severity, or delayed immune normalization that perpetuates the inflammatory state [12]. Moreover, autoantibodies emerge in approximately 40% of long COVID patients, particularly those with cardiovascular and neurological symptoms, suggesting that aberrant antibody responses contribute to persistent symptom severity [9].
Viral Persistence and Reactivation of Latent Infections
One of the most compelling proposed mechanisms for symptom persistence involves the formation of viral reservoirs—tissue compartments where SARS-CoV-2 persists beyond the acute phase despite clearing from circulation [13]. These reservoirs have been documented in the gastrointestinal tract, central nervous system, cardiovascular system, and potentially other tissues, persisting for months after initial infection. Viral RNA and proteins within these tissues perpetuate chronic inflammation and immune system disruption, contributing directly to long COVID symptoms. Although persistent viral RNA has been identified in only about 10% of severe long COVID cases examined, its presence correlates strongly with gastrointestinal symptoms and sustained immune activation [9].
Beyond direct SARS-CoV-2 persistence, the reactivation of latent herpesviruses—particularly Epstein-Barr virus (EBV) and human herpesvirus-6 (HHV-6)—under conditions of COVID-19-induced immune dysregulation contributes to prolonged symptoms in vulnerable individuals [14]. These reactivated pathogens amplify the existing inflammatory burden and may explain the considerable overlap between long COVID symptoms and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), another post-viral condition characterized by similar immune dysregulation [15].
Endothelial Dysfunction and Microvascular Complications
Patients with persistent symptoms display evidence of sustained endothelial damage and microvascular dysfunction that distinguishes them from those who recover. Elevated plasma biomarkers including prothrombin, thrombin, fibrinogen, soluble endothelial protein C receptor (sEPCR), and C-reactive protein indicate persistent endothelial dysfunction and coagulation imbalance in long COVID patients [12]. This endothelial pathology extends beyond simple coagulation alterations; it represents a fundamental vascular dysfunction characterized by inflammation, increased vascular permeability, and pro-thrombotic alterations affecting every organ system [16]. Mouse models of long COVID confirm this observation, demonstrating persistent endotheliopathy evidenced by elevated circulating markers lasting at least five months post-infection, alongside enhanced thrombotic susceptibility [17].
The vascular dysfunction in long COVID exhibits sex-specific patterns, with proteomic analysis revealing overexpression of vascular endothelial growth factor A (VEGFA) in long COVID patients, particularly in postmenopausal women [18]. This sex-specific vascular signature may partially explain the disproportionate burden of long COVID in women and suggests that hormonal status influences the likelihood of persistent endothelial dysfunction and symptom persistence.
Mitochondrial Dysfunction and Metabolic Alterations
Emerging evidence indicates that mitochondrial impairment distinguishes long COVID patients from those who recover. Telomere shortening and mitochondrial dysfunction appear as predictive biomarkers for long COVID and post-exertional malaise-associated fatigue symptoms [19]. The mechanisms underlying metabolic impairment include iron dysregulation, persistent oxidative stress, and impaired energy production that contribute to post-exertional malaise and muscle pain [20]. These metabolic alterations may explain why individuals with pre-existing metabolic dysfunction (such as obesity or diabetes) demonstrate elevated risk for symptom persistence, as their tissues begin from a compromised energetic baseline.
Autonomic Nervous System Dysfunction and Neurological Mechanisms
Persistent symptoms correlate strongly with autonomic nervous system dysfunction, particularly in patients developing post-exertional malaise and dysautonomic symptoms. Neuroinflammation and blood-brain barrier dysfunction represent key mechanisms through which SARS-CoV-2 infection triggers lasting neurological symptoms. Although direct viral infection of the brain has been difficult to demonstrate in most patients, neuroinflammatory responses triggered by viral components, circulating cytokines, and immune activation can cause persistent cognitive dysfunction, headaches, and autonomic symptoms [21]. In certain individuals, particularly those with more severe acute illness, microvascular clot formation and endothelial dysfunction compromise cerebral blood flow, contributing to cognitive impairment and other neurological manifestations [22].
Gut Dysbiosis and the Microbiota-Immune-Brain Axis
Individuals with persistent long COVID symptoms exhibit distinctive microbial dysbiosis characterized by reduced microbial diversity and depletion of beneficial short-chain fatty acid-producing species such as Faecalibacterium prausnitzii and Bifidobacterium [23]. This dysbiosis may perpetuate symptom persistence through multiple mechanisms: disruption of intestinal barrier integrity, sustained low-grade systemic inflammation, altered immune responses, and disruption of the gut-brain and gut-lung axes. Remarkably, distinct microbial signatures associate with specific symptom clusters, suggesting that microbiota composition influences which symptoms predominate in individual patients [24]. The mechanism appears to involve impaired short-chain fatty acid metabolism, tryptophan depletion, and potential bacterial translocation that sustains the inflammatory environment in long COVID patients.
Genetic and Epigenetic Contributions
Genetic predisposition influences susceptibility to both long COVID development and persistent symptom expression. Specific genetic variants contribute to increased susceptibility to pulmonary vascular complications and immune dysregulation [25]. Additionally, epigenetic changes—alterations in gene expression without changes to DNA sequence—have been documented in long COVID patients and may help explain inter-individual differences [26]. DNA methylation patterns associated with immune function, autonomic nervous system regulation, and cell metabolism have been identified in some long COVID patients, providing potential mechanisms through which genetic backgrounds influence symptom persistence through epigenetic modifications [26].
Psychological and Social Factors
Research indicates that prior mental health conditions and current psychological distress associate with higher severity of persistent symptoms [27]. Conversely, social connectedness demonstrates a protective effect against symptom persistence and psychological comorbidities [27]. This suggests that the psychological and social environment influences immune regulation and symptom resolution, with individuals experiencing social isolation, depression, or anxiety demonstrating prolonged inflammatory activation that impedes recovery. Additionally, perceived stress and work-related stress, particularly among healthcare workers, elevate the risk of long COVID persistence [28].
Individual Phenotypic Heterogeneity
Rather than representing a single disease entity, long COVID encompasses multiple distinct phenotypes or clusters of patients with different symptom profiles, underlying mechanisms, and recovery trajectories. Latent profile analyses have identified distinct clusters within long COVID populations: some patients present with predominantly neuropsychiatric and pain-related symptoms, others manifest gastrointestinal disturbances and musculoskeletal complaints, while still others display cardiopulmonary predominance [29], [30]. These phenotypic clusters likely reflect different pathophysiological drivers—potentially explaining why certain individuals develop persistent symptoms within specific organ systems while others achieve resolution. Furthermore, the number and type of symptoms reported at baseline predict persistence; patients with multiple initial symptoms face greater risk of chronicity [4], [31].
Vaccination and Viral Variant Influences
Vaccination status significantly influences long COVID risk, with unvaccinated individuals demonstrating 2.34 times higher odds of long COVID compared to vaccinated individuals [1]. Additionally, the viral variant responsible for infection influences recovery trajectory; infection during the Omicron phase demonstrates substantially lower long COVID incidence compared to earlier variants, with persistent symptoms occurring in only 9% of Omicron-infected individuals compared to 28% in pre-Omicron infections [32].
Conclusion
The persistence of long COVID symptoms results from a complex, multifactorial constellation of risk factors operating at demographic, immunological, vascular, metabolic, neurological, and microbiological levels. Rather than a single causative mechanism, symptom persistence appears to depend on cumulative burden across multiple biological systems, baseline health status, genetic predisposition, and environmental factors including vaccination status and viral exposure. Individuals progressing toward recovery typically maintain immune homeostasis, resolve viral antigens efficiently, preserve endothelial function, and sustain adequate mitochondrial energy production, while those developing persistent symptoms experience dysregulation across multiple these domains simultaneously. This heterogeneity underscores the necessity for personalized approaches to diagnosis and treatment, with recognition that long COVID comprises multiple distinct disease phenotypes requiring mechanism-targeted therapeutic strategies tailored to individual pathophysiological profiles rather than a universal treatment approach.
*Niall MacGiolla Bhuí, PhD is a researcher, ghostwriter, editor and indie publisher. He has written several books in addition to co-authoring and editing books with colleagues across several countries.
References
[1] Y. Hou, T. Gu, Z. Ni, X. Shi, M. L. Ranney, and B. Mukherjee, “Global Prevalence of Long COVID, its Subtypes and Risk factors: An Updated Systematic Review and Meta-Analysis,” medRxiv, Jan. 2025, doi: 10.1101/2025.01.01.24319384.
[2] D. Luo et al., “Prevalence and risk factors for persistent symptoms after COVID-19: a systematic review and meta-analysis.,” Clinical Microbiology and Infection, Oct. 2023, doi: 10.1016/j.cmi.2023.10.016.
[3] A. Subramanian et al., “Symptoms and risk factors for long COVID in non-hospitalized adults,” Nature Medicine, Jul. 2022, doi: 10.1038/s41591-022-01909-w.
[4] H. Akiyama et al., “Symptomatic Trends and Time to Recovery for Long COVID Patients Infected During the Omicron Phase,” Journal of Clinical Medicine, Jul. 2025, doi: 10.3390/jcm14144918.
[5] S. Chelly et al., “Symptoms and risk factors for long COVID in Tunisian population,” BMC Health Services Research, May 2023, doi: 10.1186/s12913-023-09463-y.
[6] K. Sliwa et al., “Long COVID Syndrome, Mortality and Morbidity in Patients Hospitalized with COVID-19 From 16 Countries: The World Heart Federation Global COVID-19 Study,” Global Heart, Aug. 2025, doi: 10.5334/gh.1452.
[7] A. F. Aldhawyan et al., “Evaluating the Predictors of Persistent Long COVID Symptoms and Their Severity in COVID-19 Survivors 1 Year After Infection,” Journal of Primary Care & Community Health, Jan. 2024, doi: 10.1177/21501319241295686.
[8] J. F. D. Oliveira et al., “Persistent symptoms, quality of life, and risk factors in long COVID: a cross-sectional study of hospitalized patients in Brazil,” International Journal of Infectious Diseases, Jul. 2022, doi: 10.1016/j.ijid.2022.07.063.
[9] E. Junainah et al., “Immunopathology and therapeutic strategies for long COVID: mechanisms, manifestations, and clinical implications.,” AIDS Reviews, May 2025, doi: 10.24875/AIDSRev.24000018.
[10] S. Opsteen, J. K. Files, T. R. Fram., and N. Erdmann, “The role of immune activation and antigen persistence in acute and long COVID,” Journal of Investigative Medicine, Mar. 2023, doi: 10.1177/10815589231158041.
[11] H. Liu, Z. Xu, I. Karsidag, P. Wang, and J. Weng, “Immune cell communication networks and memory CD8+ T cell signatures sustaining chronic inflammation in COVID-19 and Long COVID,” Frontiers in Immunology, Oct. 2025, doi: 10.3389/fimmu.2025.1689507.
[12] A. Simn-Rueda et al., “Immune dysregulation and endothelial dysfunction associate with a pro-thrombotic profile in Long COVID,” Frontiers in Immunology, Oct. 2025, doi: 10.3389/fimmu.2025.1613195.
[13] M. Cavarelli, “Ghosts of the virus: unmasking the persistent threat of SARS-CoV-2 in Long COVID.,” Virologie, Feb. 2025, doi: 10.1684/vir.2025.1074.
[14] A. Vojdani, E. Vojdani, E. Saidara, and M. Maes, “Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID,” Viruses, Jan. 2023, doi: 10.3390/v15020400.
[15] M. Ivanovska, M. Homadi, G. Angelova, H. Taskov, and M. A. Murdjeva, “Differential Characteristics and Comparison Between Long-COVID Syndrome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS),” Biomedicines, Nov. 2025, doi: 10.3390/biomedicines13112797.
[16] S. Turner, M. A. Khan, D. Putrino, A. Woodcock, D. Kell, and E. Pretorius, “Long COVID: pathophysiological factors and abnormalities of coagulation,” Trends in endocrinology and metabolism, Apr. 2023, doi: 10.1016/j.tem.2023.03.002.
[17] R. Aiolfi et al., “Enhanced Thrombotic Susceptibility, Endotheliopathy, and Abnormal Cognitive Behavior for up to 5 Months after Sars-Cov-2 Infection in a Mouse Model of Long COVID,” Blood, Nov. 2024, doi: 10.1182/blood-2024-212054.
[18] X. Farr et al., “VEGFA sex-specific signature is associated to long COVID symptom persistence,” BMC Medicine, Oct. 2025, doi: 10.1186/s12916-025-04402-6.
[19] A. Polli et al., “Exploring DNA methylation, telomere length, mitochondrial DNA, and immune function in patients with Long-COVID,” BMC Medicine, Feb. 2025, doi: 10.1186/s12916-025-03881-x.
[20] G. Gupta, D. Buonsenso, J. C. Wood, S. Mohandas, and D. Warburton, “Mechanistic Insights Into Long Covid: Viral Persistence, Immune Dysregulation, and MultiOrgan Dysfunction,” Comprehensive Physiology, Jun. 2025, doi: 10.1002/cph4.70019.
[21] A. Leng et al., “Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics,” Cells, Mar. 2023, doi: 10.3390/cells12050816.
[22] V. Crdenas, “Neurological Manifestations of Post-Viral Syndromes and Long COVID: Clinical Spectrum and Pathophysiological Mechanisms (Qualitative Systematic Review),” Frontiers, Jan. 2026, doi: 10.11648/j.frontiers.20260601.12.
[23] O. Caliman-Sturdza, S. Hamamah, O. C. Iatcu, A. Lobiuc, A. Bosancu, and M. Cova, “Microbiome and Long COVID-19: Current Evidence and Insights,” International Journal of Molecular Sciences, Oct. 2025, doi: 10.3390/ijms262010120.
[24] A. Zollner, M. Meyer, A. Jukic, T. Adolph, and H. Tilg, “The Intestine in Acute and Long COVID: Pathophysiological Insights and Key Lessons,” The Yale Journal of Biology and Medicine, Dec. 2024, doi: 10.59249/PMIE8461.
[25] S. Ayyoub, N. K. Dhillon, and O. Tura-Ceide, “Genetics of Long COVID: Exploring the Molecular Drivers of Persistent Pulmonary Vascular Disease Symptoms,” Infectious Disease Reports, Feb. 2025, doi: 10.3390/idr17010015.
[26] M. S. Patil et al., “Epigenetic changes in patients with post-acute COVID-19 symptoms (PACS) and long-COVID: A systematic review,” Expert Reviews in Molecular Medicine, Oct. 2024, doi: 10.1017/erm.2024.32.
[27] S. Kananian, A. Nemani, and U. Stangier, “Risk and protective factors for the severity of long COVID - A network analytic perspective.,” Journal of Psychiatric Research, Aug. 2024, doi: 10.1016/j.jpsychires.2024.08.031.
[28] H. Chen et al., “Prevalence and factors influencing long COVID among primary healthcare workers after epidemic control policy adjustment in Jiangsu, China,” BMC Infectious Diseases, Sep. 2024, doi: 10.1186/s12879-024-09764-5.
[29] C. C. Fernandez et al., “Profiles of Individuals With Long COVID Reporting Persistent Cognitive Complaints,” Archives of Clinical Neuropsychology, Jul. 2025, doi: 10.1093/arclin/acaf064.
[30] A. B. Yonts, P. Dwivedi, J. Bost, M. Geslak, E. McLaughlin, and E. Ansusinha, “P-521. The Many Faces of Pediatric Long COVID: A Phenotypic Cluster Analysis of Symptoms in Children Presenting to a Multidisciplinary Pediatric Long COVID Clinic,” Open Forum Infectious Diseases, Jan. 2026, doi: 10.1093/ofid/ofaf695.736.
[31] M. Floridia et al., “Adolescents with Persistent Symptoms Following Acute SARS-CoV-2 Infection (Long-COVID): Symptom Profile, Clustering and Follow-Up Symptom Evaluation,” Children, Dec. 2024, doi: 10.3390/children12010028.
[32] I. Moritani et al., “Prevalence of and risk factors for long COVID following infection with the COVID19 omicron variant,” Medicine International, Jan. 2025, doi: 10.3892/mi.2025.216.